89Zr抗体替代225Ac抗体预测肿瘤与器官剂量的可行性研究
该研究在肾细胞癌小鼠模型中,比较两种抗CAIX抗体(hG250和FcRn(-)hG250)分别标记89Zr和225Ac后的体内分布与剂量学,评估89Zr能否作为225Ac的替代进行剂量预测。结果显示FcRn(-)hG250组预测肿瘤剂量高估3.9±2.0 Gy(6±50.6%),而hG250组低估1413.7±629.1 Gy(69±44.5%),且脱靶器官(肝、脾)偏差最明显,提示预测准确性因抗体而异。
要点
- FcRn(-)hG250的89Zr/225Ac分布可比,肿瘤剂量预测较准。
- hG250的肿瘤、脾、肝摄取差异显著,预测偏差大。
- 89Zr-PET用于225Ac剂量预测需进一步研究验证。
核心结论
- 89Zr/225Ac诊疗对在ccRCC小鼠模型中的肿瘤和器官剂量预测准确性因所用抗体而异。
- FcRn(-)hG250可实现较准确的肿瘤剂量估计,而hG250因摄取不匹配限制了预测。
研究设计与样本
- 在荷SK-RC-52皮下肿瘤的BALB/c裸鼠中,静脉注射25-50 kBq 225Ac标记或1 MBq 89Zr标记的抗CAIX抗体,蛋白剂量相等。
- 基于FcRn(-)hG250在4、24、72、168小时的摄取数据,以及hG250在24、72、168小时的摄取数据进行器官和肿瘤吸收剂量计算。
- 通过比较基于89Zr抗体的预测225Ac吸收剂量与实测225Ac吸收剂量,评估89Zr对225Ac的预测价值。
主要发现
- FcRn(-)hG250的89Zr/225Ac诊疗对生物分布特征可比。
- hG250的肿瘤、脾和肝摄取存在显著差异。
- FcRn(-)hG250组预测225Ac肿瘤剂量高估3.9±2.0 Gy(6±50.6%)。
- hG250组预测225Ac肿瘤剂量低估1413.7±629.1 Gy(69±44.5%)。
- 两种抗体的脱靶器官中,肝和脾的预测与实测225Ac剂量偏差最明显。
临床怎么用
- 在应用89Zr-PET预测225Ac治疗剂量前,需验证特定抗体在89Zr和225Ac标记下的生物分布一致性。
- 对于生物分布不匹配的抗体,基于89Zr的剂量预测可能不可靠,应谨慎解读。
局限性
- 研究仅基于ccRCC小鼠模型,结论外推至人体需谨慎。
- 预测准确性因抗体而异,可能受225Ac和89Zr固有性质及生物学效应差异影响。
- 需进一步研究89Zr-PET如何用于225Ac-TRT剂量预测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The aim of this study was to assess whether zirconium-89 (89Zr)-labelled antibodies can act as a surrogate for actinium-225 (225Ac)-labelled antibodies to predict tumour- and organ dose. To this end, we performed ex vivo biodistribution and dosimetry studies with two anti-CAIX antibodies (hG250 and FcRn(-)hG250), radiolabelled with 89Zr and 225Ac, in a renal cell carcinoma mouse model. METHODS: BALB/c nude mice bearing subcutaneous SK-RC-52 tumours were injected intravenously with 25-50 kBq 225Ac-labelled or 1 MBq 89Zr-labelled anti-CAIX antibody, at equal protein dose. Organ and tumour absorbed doses were calculated based on the uptake data at 4, 24, 72, and 168 h for FcRn(-)hG250 and 24, 72, and 168 h for hG250. The predictive value of 89Zr for 225Ac was evaluated in both groups, by comparing the predicted 225Ac absorbed dose (based on 89Zr-antibody) and the measured 225Ac absorbed dose. RESULTS: The biodistribution profile of the theranostic pair 89Zr/225Ac was comparable for FcRn(-)hG250. For hG250, significant discrepancies between tumour, spleen and liver uptake were observed. The predicted 225Ac tumour dose was overestimated by 3.9 ± 2.0 Gy (6 ± 50.6%) and underestimated by 1413.7 ± 629.1 Gy (69 ± 44.5%) in the FcRn(-)hG250 and hG250 groups, respectively. The deviation of the predicted versus measured 225Ac-dose in off-target organs was most notable in liver and spleen for both antibodies. CONCLUSION: This study highlights variability in the predictive accuracy of the 89Zr/225Ac theranostic pair for tumour and organ dosimetry in a ccRCC mouse model, depending on the antibody used. FcRn(-)hG250 enabled accurate tumour dose estimation, whereas hG250 showed mismatched uptake limiting prediction, possibly due to inherent differences in the properties and biological effects of both 225Ac and 89Zr. These findings underscore the need to further investigate how 89Zr-PET can be used for 225Ac-TRT dose prediction.
引用
- Merkx RIJ, Kleinendorst SC, Rijpkema M, et al. Predicting tumour and organ dose in α-radiopharmaceutical therapy: a 89Zr-based dosimetric approach for 225Ac. Eur J Nucl Med Mol Imaging. 2026. PMID: 42455315. doi:10.1007/s00259-026-08076-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。